TEST:

nCounter® Breast Cancer 360™ Panel

Additionally, SMRwt suppresses ASC-mediated caspase-1 activation and reduces IL-1β secretion, thereby inhibiting NLRP3 inflammasome signaling. Therefore, we infer that SMRwt simultaneously restores tumor-suppressive miRNA networks and suppresses inflammasome-driven inflammation, supporting its potential as a dual-target therapeutic strategy for TNBC.

Spatially resolved tumour and TME across a patient's lumpectomy demonstrated substantial heterogeneity in the expression of commonly targeted immune and tumour proteins. Results from this study demonstrated heterogeneity across the tumour and TME in ER+ breast cancer, which may be reflective of a variable immune response.

RNA-based breast cancer subtyping suggests TP53 refines breast cancer etiologic heterogeneity in a sub-Saharan African population. The high prevalence of aggressive, mostly TP53-mutant tumors in this population underscores the need for further studies to clarify etiologic heterogeneity.

No 3-year breast cancer-specific survival events are observed in these patients. These data provide a rationale for CT-sparing trials in this setting.

Endocrine resistance in luminal breast cancer is characterized by elevated immune signatures, increased proliferation, and specific genomic alterations. The integration of clinical information, gene expression patterns, and genetic data enhances patient stratification and potentially informs treatment decisions. These findings support the use of integrative analyses to guide personalized endocrine therapy and improve outcomes.

Patients from deprived areas exhibited higher inflammation and antioxidant depletion even within the same tumor grade (p < 0.05). Neighborhood deprivation correlates with pro-inflammatory, proliferative multiomic profiles that may underlie worsened outcomes.

Using multiplex IHC and transcriptome analyses, this study demonstrated that PABC was associated with a higher abundance of immune cells, including increased infiltration of T cells, B cells, and macrophages, in the breast tumor microenvironment. Future research is required to focus on the role of immune cells in pregnancy-associated breast cancer patients.

This study highlights the unique molecular and biological features of metastatic EMPD, emphasizing the need for tailored treatment approaches. This information should be used to guide future clinical strategies for metastatic EMPD.

Non-luminal intrinsic subtypes are prevalent in BCBMs and basal-like genomic features are associated with worse survival. Recurrent gene expression modifications with potential therapeutic implications were observed in BCBMs.

This study reinforces the prognostic utility of histological grading and reveals a set of cell cycle-related genes whose overexpression is linked to adverse outcomes in breast cancer. These findings suggest potential biomarkers for risk stratification and therapeutic targeting, offering insights for personalized management of patients beyond traditional histological assessments.

ER-negative, HER2-positive breast cancer has unique molecular and immunologic features that may predict pCR after neoadjuvant HP. Validation of these potential biomarkers and composite biomarker analyses may guide design of future clinical trials.

Interestingly, differences emerged when comparing patients diagnosed during gestation (PABC-GS) and the postpartum period (PABC-PP), with PABC-PP showing increased expression of immune-related genes, including PD-1, and greater immune cell infiltration (Tregs, macrophages, neutrophils, B-cells). These findings suggest an enhanced proliferative capacity and impaired DNA repair in PABC, and underscore the role of immune infiltration in postpartum cases; providing insights into its aggressive nature and potential targets.